Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics executive Larry Todd Edwards reported a small insider sale of common stock. On February 2, 2026, he sold 2,052 shares at a weighted average price of $25.4984 per share, solely to cover tax withholding obligations from vesting restricted stock units (RSUs).
The RSUs were granted on January 12, 2024 and vest 25% annually each February 1, beginning in 2025, subject to continued service. After this tax-related sale, Edwards beneficially owns 148,865 shares, including 724 shares purchased under the company’s Employee Stock Purchase Plan on November 30, 2025.
Arcutis Biotherapeutics insider plans stock sale under Rule 144. A holder named Patrick Burnett filed notice to sell 9,794 shares of Arcutis common stock through Merrill Lynch, with an aggregate market value of $252,748.08, on or about 02/04/2026 on the NASDAQ.
The 9,794 shares to be sold were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The filing also lists several prior open‑market sales of Arcutis common shares by the same holder over the past three months, with disclosed share amounts and gross proceeds for each transaction.
Masaru Matsuda filed a notice to sell 40,638 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026. The aggregate market value of the planned sale is 1,027,275 based on the filing data, versus 122,492,192 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting from Arcutis Biotherapeutics on multiple dates, including 02/01/2026, 02/01/2025, 11/18/2024, 11/01/2024, and 08/01/2024, in amounts that total 40,638 shares. In the past three months, Matsuda also sold 1,675 shares on 12/01/2025 for gross proceeds of 50,041 and 2,550 shares on 11/19/2025 for gross proceeds of 72,056.
Arcutis Biotherapeutics insider Todd Edwards filed a notice to sell 2,052 shares of common stock under Rule 144. The planned sale, through Merrill on NASDAQ, has an aggregate market value of $52,322.72 and an approximate sale date of February 2, 2026.
The shares to be sold were acquired as restricted stock that vested on February 1, 2026 from Arcutis Biotherapeutics Inc. The filing also reports that Edwards sold 29,131 common shares on November 6, 2025 for gross proceeds of $732,051.95 during the prior three months.
A shareholder of Arcutis Biotherapeutics plans to sell 1,320 common shares under Rule 144. The shares have an aggregate market value of $33,657.89, with Arcutis having 122,492,192 shares outstanding. The sale, through Merrill Lynch on NASDAQ, is expected around February 2, 2026.
The seller acquired the 1,320 shares on February 1, 2026 via restricted stock vesting from Arcutis Biotherapeutics, with payment on the same date. Over the prior three months, the same person sold 88 common shares on November 3, 2025 for gross proceeds of $2,155.
Arcutis Biotherapeutics insider schedules sale of restricted shares under Rule 144. A holder has filed to sell 3,675 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on or about 02/02/2026 on the NASDAQ, with an aggregate market value listed at $93,706.62.
These shares were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The notice also lists several prior sales of Arcutis common stock by Patrick Burnett during the past three months, each with specified dates, share amounts, and gross proceeds.
Arcutis Biotherapeutics insider activity: A holder has filed to sell 19,833 shares of Arcutis Biotherapeutics common stock under Rule 144 through Merrill on the NASDAQ, with an approximate sale date of 02/02/2026. The filing notes 122,492,192 common shares outstanding for this class.
The 19,833 shares were acquired on 02/01/2026 via a restricted stock vest from Arcutis Biotherapeutics, Inc., with payment also dated 02/01/2026. In the prior three months, Todd F. Watanabe reported sales of 48,945 and 1,055 common shares, with gross proceeds of 1,485,759 and 31,650, respectively.
Arcutis Biotherapeutics insider Howard Welgus filed a Rule 144 notice to sell 10,000 shares of common stock through Merrill, with an aggregate market value of $250,482.69. The shares relate to a stock option exercise on 06/04/2018, paid in cash.
Welgus reports prior sales over the past three months of 10,000 shares each on 11/03/2025, 12/01/2025, and 01/02/2026, with gross proceeds of $252,668.51, $302,133.02, and $289,606.03. The planned sale is expected around 02/02/2026 on NASDAQ, where 122,492,192 shares of the issuer’s common stock are outstanding.
Jennison Associates LLC reports beneficial ownership of 6,758,006 shares of Arcutis Biotherapeutics Inc. common stock, representing 5.5% of the outstanding class as of 12/31/2025. Jennison has sole power to vote these shares and shared power to dispose of them.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Arcutis. The filing is signed by a Senior Vice President, Compliance, on behalf of Jennison Associates LLC.
Arcutis Biotherapeutics, Inc. Executive Vice President and Chief Medical Officer Patrick Burnett reported a planned sale of company stock. On January 5, 2026, he sold 2,490 shares of Arcutis common stock at a weighted average price of $28.9822 per share under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After this transaction, he beneficially owned 94,120 shares of Arcutis common stock directly.